Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Apr 14;12(4):e0175564.
doi: 10.1371/journal.pone.0175564. eCollection 2017.

The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice

Affiliations
Comparative Study

The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice

J A Fernández-Caballero et al. PLoS One. .

Abstract

Objective: We aimed to evaluate the correct assignment of HCV genotype/subtypes 1a and 1b by cobas® HCV genotyping (GT) assay (Roche Molecular Diagnostics) compared with nonstructural protein 5B (NS5B) sequencing.

Patients and methods: Clinical samples from 153 patients submitted for HCV genotyping were studied. After genotyping with the cobas® HCV GT, sequencing of a 387 bp fragment in the NS5B gene and phylogenetic analysis was employed to compare genotyping results. Major discrepancies were defined as differences in the assigned genotype by cobas® HCV GT and NS5B sequencing (including genotype 1 subtypes 1a and 1b misclassification).

Results: Overall agreement between the cobas® HCV GT and NS5B sequencing was 98%; all the 1a, 1b, 2, 3 and 4 genotypes identified by cobas® HCV GT were concordant with NS5B sequencing. Three samples tested "indetermined" by cobas® HCV GT assay and were genotyped as 1a, 3a, and 4d by NS5B sequencing.

Conclussion: These results indicate that the cobas® HCV GT assay correctly identifies HCV genotypes, and points out the importance of additional methods based on DNA sequencing for resolving indeterminate results.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Federico García has received payment for speaking services and consultancy from Roche, Abbvie, MSD, ViiV healthcare, Janssen and Gilead. No other financial conflicts of interest for any other author. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Similar articles

Cited by

References

    1. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017; 66(1): 153–194. 10.1016/j.jhep.2016.09.001 - DOI - PubMed
    1. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3): 932–54. 10.1002/hep.27950 - DOI - PubMed
    1. Sistema Nacional de Salud. Plan estratégico para el abordaje de la Hepatitis C en el sistema nacional de salud. Ministerio de Sanidad, Servicios sociales e igualdad. 21 may 2015. http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/pla...
    1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61(1): 77–87. 10.1002/hep.27259 - DOI - PMC - PubMed
    1. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology. 2015; 62(5): 1623–32. 10.1002/hep.27934 - DOI - PubMed

Publication types